Component manufacturer Analogic reported record revenue of $29.76 million for the year (ended July 31), compared with $27.96 million a year ago. But the company had a drop in net income for the year of $14.1 million, compared with $19.5 million a year
Component manufacturer Analogic reported record revenue of $29.76 million for the year (ended July 31), compared with $27.96 million a year ago. But the company had a drop in net income for the year of $14.1 million, compared with $19.5 million a year earlier.
Analogic's fourth quarter numbers, however, showed a profit of $5.4 million, compared with $3.9 million for the same quarter a year earlier.
"The solid growth demonstrated in our record fourth quarter was due to increased shipments of both medical and industrial products," said Bernard M. Gordon, Analogic's CEO.
The company ships digital radiography systems, ultrasound engines, and connectivity devices, as well as complete ultrasound and CT scanners, to domestic and foreign companies that attach their own labels, said Tom Miller, president and COO.
"We're at the front end and the tail end of systems such as Kodak's DR products (SCAN 10/25/00)," Miller said.
All commercial selenium x-ray plates are coated by Anrad, a wholly owned Analogic subsidiary, he said. These are then supplied to Hologic/DRC, which completes the electronics for plates. Analogic purchases the plates and integrates them with Fischer Imaging components such as generators and table stands, and sells the finished product to Kodak.
Analogic does not really compete with other companies, Miller said, but rather with the R&D sections of the OEMs. It must be able to supply them with high-end products that are better than the ones they could have manufactured themselves.
Miller would not identify Analogic's other OEM customers.
"They want to stick the Made in Japan' or Made in Germany' or Made in Milwaukee' labels on them, so we'll let them identify themselves if they want to," he said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.